Shishido-Hara Y - Search Results

1

Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.

Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M. Nitta Y, et al. Cancer Med. 2016 Mar;5(3):486-99. doi: 10.1002/cam4.614. Epub 2016 Jan 18. Cancer Med. 2016. PMID: 26778701 Free PMC article.

2

Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.

Nagane M, Kobayashi K, Tanaka M, Tsuchiya K, Shishido-Hara Y, Shimizu S, Shiokawa Y. Nagane M, et al. Int J Clin Oncol. 2014 Feb;19(1):16-23. doi: 10.1007/s10147-013-0517-x. Epub 2013 Jan 26. Int J Clin Oncol. 2014. PMID: 23354833

3

JC virus inclusions in progressive multifocal leukoencephalopathy: scaffolding promyelocytic leukemia nuclear bodies grow with cell cycle transition through an S-to-G2-like state in enlarging oligodendrocyte nuclei.

Shishido-Hara Y, Yazawa T, Nagane M, Higuchi K, Abe-Suzuki S, Kurata M, Kitagawa M, Kamma H, Uchihara T. Shishido-Hara Y, et al. J Neuropathol Exp Neurol. 2014 May;73(5):442-53. doi: 10.1097/NEN.0000000000000066. J Neuropathol Exp Neurol. 2014. PMID: 24709678 Free PMC article.

4

Genomic characterization of primary central nervous system lymphoma.

Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee J, Shishido-Hara Y, Sasaki A, Shirahata M, Mishima K, Ichimura K, Mukasa A, Narita Y, Saito N, Aburatani H, Nishikawa R, Nagane M, Mano H. Fukumura K, et al. Acta Neuropathol. 2016 Jun;131(6):865-75. doi: 10.1007/s00401-016-1536-2. Epub 2016 Jan 12. Acta Neuropathol. 2016. PMID: 26757737

5

Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy.

Lee J, Shishido-Hara Y, Suzuki K, Shimizu S, Kobayashi K, Kamma H, Shiokawa Y, Nagane M. Lee J, et al. Jpn J Clin Oncol. 2017 Oct 1;47(10):925-934. doi: 10.1093/jjco/hyx098. Jpn J Clin Oncol. 2017. PMID: 28981733

6

Cyclic AMP-mediated growth suppression and MAPK phosphorylation in thyroid papillary carcinoma cells.

Matsumoto H, Sakamoto A, Fujiwara M, Yano Y, Shishido-Hara Y, Fujioka Y, Kamma H. Matsumoto H, et al. Mol Med Rep. 2008 Mar-Apr;1(2):245-9. Mol Med Rep. 2008. PMID: 21479404

7

Class III/IV POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation.

Ishii J, Sato H, Yazawa T, Shishido-Hara Y, Hiramatsu C, Nakatani Y, Kamma H. Ishii J, et al. Pathol Int. 2014 Sep;64(9):415-22. doi: 10.1111/pin.12198. Pathol Int. 2014. PMID: 25243889

8

PROX1 Promotes Secretory Granule Formation in Medullary Thyroid Cancer Cells.

Ishii J, Yazawa T, Chiba T, Shishido-Hara Y, Arimasu Y, Sato H, Kamma H. Ishii J, et al. Endocrinology. 2016 Mar;157(3):1289-98. doi: 10.1210/en.2015-1973. Epub 2016 Jan 13. Endocrinology. 2016. PMID: 26760117

9

Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumors (GISTs): a potential marker for tumor proliferation.

Hirano K, Shishido-Hara Y, Kitazawa A, Kojima K, Sumiishi A, Umino M, Kikuchi F, Sakamoto A, Fujioka Y, Kamma H. Hirano K, et al. Pathol Res Pract. 2008;204(11):799-807. doi: 10.1016/j.prp.2008.05.002. Epub 2008 Jul 3. Pathol Res Pract. 2008. PMID: 18602222

10

Expression of developing neural transcription factors in lung carcinoid tumors.

Endo T, Yazawa T, Shishido-Hara Y, Fujiwara M, Shimoyamada H, Ishii J, Sato H, Tachibana K, Takei H, Kondo H, Goya T, Endo S, Kamma H. Endo T, et al. Pathol Int. 2014 Aug;64(8):365-74. doi: 10.1111/pin.12183. Pathol Int. 2014. PMID: 25143124

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters